DAPADAX VG 5/50 (Dapagliflozin (5mg) + Vildagliptin (50mg))

DAPADAX VG 5/50 is a pharmaceutical formulation that combines two active components: Dapagliflozin at a dosage of 5 mg and Vildagliptin at 50 mg. This combination is designed to support the management of type 2 diabetes mellitus. Dapagliflozin belongs to the class of medications known as SGLT2 inhibitors, which function by promoting the removal of glucose from the bloodstream through urine. This mechanism aids in lowering overall blood sugar levels. On the other hand, Vildagliptin is classified as a DPP-4 inhibitor. It works by increasing levels of incretin hormones, which in turn boosts insulin secretion when food is consumed and decreases glucagon levels, helping to stabilize blood glucose levels after meals. The synergistic effect of these two medications contributes to better glycemic control and can potentially lower the likelihood of complications associated with diabetes. Patients using DAPADAX VG 5/50 should do so under the guidance of a healthcare provider, as regular monitoring of blood sugar levels and overall diabetes management will be necessary to ensure optimal efficacy and safety. Use this medicine only under medical supervision. Follow the dose and schedule exactly as advised. Do not stop abruptly without guidance. Keep a record of any unusual symptoms and share them with your clinician. Combine therapy with appropriate lifestyle measures and routine monitoring as recommended.